Ignyta, Inc. is a scientifically driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Our goals are to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide.
Find out more
 
   
 
   
    Technology Platform
    Our proprietary platform uses next generation genomic, epigenomic, and other molecular technologies to optimize biomarker and target accuracy
    Find out More
   
 
   
    Scientific Presentations and Publications
    Peer reviewed scientific data help guide our diagnostic and therapeutic development decisions
    Find out More
 Recent News  
 5.06.13
 Ignyta and UC San Diego Researchers Find that Permanent...
read more
 3.20.13
 Ignyta Appoints Dr. Tom Huizinga to Scientific Advisory...
read more
 2.28.13
 Ignyta Raises Additional $1M Through Capital Term Loan ...
read more
More News